Furthermore, we were unable to access and analyze emergingbiomarkers of AKI such as neutrophil gelatinase-associated lipocalin, kidneyinjury molecule-1, and cystatin C. The inclusion of these biomarkers could haveprovided a more comprehensive understanding of the pathophysiological changes andrisk stratification in our patient population, potentially enhancing thepredictive accuracy of our findings. The gene discussed is LCN2; the disease is acute kidney injury.